Johnson & Johnson's Tecvayli has been approved as part of a combination regimen with its Genmab-partnered Darzalex Faspro as a second-line therapy for relapsed or refractory multiple myeloma, just 55 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results